Exelixis
EXEL
#1458
Rank
HK$116.39 B
Marketcap
HK$469.73
Share price
1.42%
Change (1 day)
58.22%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): HK$25.78

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$25.90. In 2025 the company made an earnings per share (EPS) of HK$22.68.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)HK$25.7813.66%
2025HK$22.68
2023HK$5.1314.61%
2022HK$4.47-22.97%
2021HK$5.81100%
2020HK$2.90-65.09%
2019HK$8.32-53.91%
2018HK$18.05333.96%
2017HK$4.16-260.61%
2016-HK$2.59-58.75%
2015-HK$6.28-42.45%
2014-HK$10.915.3%
2013-HK$10.36

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
HK$68.54 164.66%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$5.96-76.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$127.28 391.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$14.93-42.34%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$9.93-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$35.63 37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$25.09-3.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$111.59-530.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$6.59-125.45%๐Ÿ‡บ๐Ÿ‡ธ USA